Abivax (ABVX) Income from Continuing Operations (2022 - 2026)
Abivax's (ABVX) quarterly Income from Continuing Operations came in at 56476770.16 in Q1 2026, down 2.52% year-on-year from 57938271.19 in Q1 2025, and up 36.29% quarter-over-quarter from 88651225.99 in Q4 2025.
Abivax (ABVX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Abivax's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 56476770.16 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 2.52% year-over-year to 56476770.16 in Q1 2026; TTM through Mar 2026 was 379214643.19, a 90.06% decrease from a year earlier, with the FY2025 full-year figure at 391290899.38, down 105.18% from the prior year.
- Income from Continuing Operations grew to 56476770.16 in Q1 2026 per ABVX's latest filing, from 88651225.99 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 41750931.33 in Q2 2024 and bottomed at 179283950.7 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 56476770.16 (2026), against an average of 75317658.48.
- Across the five-year window, Income from Continuing Operations jumped 69.33% in 2024 and slumped 195.6% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 66112029.27 in 2022, then tumbled by 107.34% to 137074744.4 in 2023, then soared by 69.33% to 42034268.66 in 2024, then plunged by 110.9% to 88651225.99 in 2025, then soared by 36.29% to 56476770.16 in 2026.
- Per Business Quant, the three latest ABVX Income from Continuing Operations figures stand at 56476770.16 (Q1 2026), 88651225.99 (Q4 2025), and 179283950.7 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - | -56.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.48 Mn |
| Dec 31, 2025 | -88.65 Mn |
| Sep 30, 2025 | -179.28 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -55.09 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -60.65 Mn |
| Jun 30, 2024 | -41.75 Mn |
| Mar 31, 2024 | -46.57 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |